CHRS
Coherus Biosciences Inc

5,008
Mkt Cap
$159.55M
Volume
317,134.00
52W High
$1.89
52W Low
$0.71
PE Ratio
-0.83
CHRS Fundamentals
Price
$1.34
Prev Close
$1.32
Open
$1.32
50D MA
$1.42
Beta
1.81
Avg. Volume
1.42M
EPS (Annual)
$0.2482
P/B
1.75
Rev/Employee
$1.17M
Loading...
Loading...
News
all
press releases
Coherus Oncology (NASDAQ:CHRS) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above Two Hundred Day Moving Average - Here's What Happened...
MarketBeat·11h ago
News Placeholder
More News
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200 Day Moving Average - Here's Why
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above Two Hundred Day Moving Average - What's Next...
MarketBeat·23d ago
News Placeholder
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Rating of "Hold" by Brokerages
Shares of Coherus Oncology, Inc. (NASDAQ:CHRS - Get Free Report) have earned a consensus recommendation of "Hold" from the five ratings firms that are covering the firm, MarketBeat.com reports. One...
MarketBeat·1mo ago
News Placeholder
Los Angeles Capital Management LLC Has $284,000 Stake in Coherus Oncology, Inc. $CHRS
Los Angeles Capital Management LLC reduced its position in Coherus Oncology, Inc. (NASDAQ:CHRS - Free Report) by 60.9% in the 2nd quarter, according to the company in its most recent disclosure with...
MarketBeat·1mo ago
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Raised to Hold at Wall Street Zen
Wall Street Zen raised shares of Coherus Oncology from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·2mo ago
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results
Coherus Oncology (NASDAQ:CHRS - Get Free Report) posted its earnings results on Thursday. The biotechnology company reported ($0.33) earnings per share for the quarter, topping analysts' consensus...
MarketBeat·2mo ago
News Placeholder
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -3.13% and -5.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Illumina (ILMN) Beats Q3 Earnings and Revenue Estimates
Illumina (ILMN) delivered earnings and revenue surprises of +15.52% and +1.73%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -9.68% and +1.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of +100.00% and +593.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
<
1
2
...
>

Latest CHRS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.